Employer record no. 14192
Lyell Immunopharma, Inc.
US DOL LCA disclosure data, FY2020 to FY2026
Total LCA filings
24
Certified
15
Denied
0
FY2025 filings
2
Filings by fiscal year
* partial fiscal year; quarters still being published by DOL
Peer rank
#1,206 of 2,686 healthcare employers by filings
The ledger
| Fiscal year | Filed | Certified | Denied | Avg offered wage | Avg prevailing |
|---|---|---|---|---|---|
| FY2020 | 3 | 1 | 0 | $165,000 | $121,729 |
| FY2021 | 7 | 6 | 0 | $201,337 | $159,179 |
| FY2022 | 5 | 2 | 0 | $150,785 | $127,866 |
| FY2023 | 4 | 4 | 0 | $198,661 | $174,970 |
| FY2024 | 2 | 0 | 0 | $177,262 | $167,357 |
| FY2025 | 2 | 1 | 0 | $152,085 | $150,316 |
| FY2026 * | 1 | 1 | 0 | $291,304 | $291,304 |
What they file for
- senior business analyst, financial systems$165,0003
- sr. business analyst, financial systems$158,6293
- sr. director of total rewards$267,0943
- clinical data platform product manager$200,0002
- manager of regulatory$133,0002
- research associate ii, tme & tce$98,3252
- senior scientist, translational pathology laboratory$154,5002
- sr. director, total rewards$236,6392
Where
- south san francisco, ca17
- seattle, wa6
- redwood city, ca1
Every number on this page is free. Members get an email when this employer files again, a CSV of the full record, and the complete rankings with state and job-title filters.
Watch this employerGet the quarterly H-1B update, free
When DOL publishes new filings we send what changed: the biggest movers and the slimmest wage premiums. No account needed. Members also get alerts for Lyell Immunopharma, Inc. and any other employer they watch.
Certification rate 62.5%How these numbers are computed